XTL Biopharmaceuticals Ltd (H2K2) - Total Liabilities
Based on the latest financial reports, XTL Biopharmaceuticals Ltd (H2K2) has total liabilities worth €3.12 Million EUR (≈ $3.64 Million USD) as of December 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore investment intensity of XTL Biopharmaceuticals Ltd to see how much of total assets are deployed in long-term investments.
XTL Biopharmaceuticals Ltd - Total Liabilities Trend (2016–2024)
This chart illustrates how XTL Biopharmaceuticals Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see H2K2 current and non-current assets.
XTL Biopharmaceuticals Ltd Competitors by Total Liabilities
The table below lists competitors of XTL Biopharmaceuticals Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Grosvenor Resource Corp
V:GVR
|
Canada | CA$23.93K |
|
China SXT Pharmaceuticals Inc
NASDAQ:SXTC
|
USA | $5.05 Million |
|
KOOL2PLAY S.A. ZY -10
F:8Q8
|
Germany | €3.89 Million |
|
Solid State Plc
LSE:SOLI
|
UK | GBX43.90 Million |
|
Iofina plc
LSE:IOF
|
UK | GBX23.53 Million |
|
Allurion Technologies, Inc.
NYSE:ALUR
|
USA | $91.91 Million |
|
Antarctica Limited
NSE:ANTGRAPHIC
|
India | Rs374.55 Million |
Liability Composition Analysis (2016–2024)
This chart breaks down XTL Biopharmaceuticals Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See XTL Biopharmaceuticals Ltd balance sheet independence to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.61 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.57 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.36 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how XTL Biopharmaceuticals Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for XTL Biopharmaceuticals Ltd (2016–2024)
The table below shows the annual total liabilities of XTL Biopharmaceuticals Ltd from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €3.12 Million ≈ $3.64 Million |
+1412.14% |
| 2023-12-31 | €206.00K ≈ $240.84K |
+10.16% |
| 2022-12-31 | €187.00K ≈ $218.62K |
-85.45% |
| 2021-12-31 | €1.28 Million ≈ $1.50 Million |
+405.91% |
| 2020-12-31 | €254.00K ≈ $296.95K |
+9.48% |
| 2019-12-31 | €232.00K ≈ $271.23K |
-8.30% |
| 2018-12-31 | €253.00K ≈ $295.78K |
-91.47% |
| 2017-12-31 | €2.97 Million ≈ $3.47 Million |
+799.09% |
| 2016-12-31 | €330.00K ≈ $385.80K |
-- |
About XTL Biopharmaceuticals Ltd
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. The company has a licensing agreement with Yeda Research and Development Company L… Read more